Su-Pin Choo

List of Publications by Year
in descending order

93 papers	8,707 citations	126907 33 h-index	48315 88 g-index
97 all docs	97 docs citations	97 times ranked	11166 citing authors

#	Article	IF	Citations
1	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	13.7	3,224
2	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	9.4	637
3	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	10.7	526
4	SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. Journal of Clinical Oncology, 2018, 36, 1913-1921.	1.6	467
5	Exome sequencing identifies distinct mutational patterns in liver flukeâ€"related and non-infection-related bile duct cancers. Nature Genetics, 2013, 45, 1474-1478.	21.4	426
6	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	3.7	310
7	Comparison of hepatocellular carcinoma in <scp>E</scp>astern versus <scp>W</scp>estern populations. Cancer, 2016, 122, 3430-3446.	4.1	221
8	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 2019, 71, 543-552.	3.7	180
9	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer, 2020, 9, 245-260.	7.7	172
10	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	9.4	157
11	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1371-1380.	3.6	128
12	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology, 2021, 75, 600-609.	3.7	127
13	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 2673-2683.	3.6	118
14	The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nature Communications, 2017, 8, 4565.	12.8	117
15	A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. Hpb, 2016, 18, 7-12.	0.3	95
16	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine, 2016, 8, 195-202.	6.1	94
17	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). Journal of Hepatology, 2010, 52, 79-87.	3.7	88
18	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Frontiers in Immunology, 2020, 11, 568759.	4.8	79

#	Article	IF	Citations
19	Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabineâ€“Induced Hand-Foot Syndrome. JAMA Oncology, 2017, 3, 1538.	7.1	72
20	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
21	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 4650-4661.	7.0	63
22	Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Scientific Reports, 2017, 7, 40737.	3.3	62
23	Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e90909.	2.5	59
24	Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 1025-1035.	8.1	56
25	Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. Frontiers in Immunology, 2019, 10, 2093.	4.8	51
26	Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 595-601.	3.7	50
27	A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Annals of Oncology, 2016, 27, 2210-2215.	1.2	48
28	National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer, 2016, 5, 97-106.	7.7	47
29	The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0118658.	2.5	46
30	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 683-694.	3.7	45
31	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988900.	3.2	44
32	Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatology International, 2014, 8, 395-404.	4.2	41
33	Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling. European Radiology, 2009, 19, 1184-1196.	4.5	36
34	Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e68904.	2.5	36
35	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Global Oncology, 2020, 6, 628-638.	1.8	35
36	Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocrine-Related Cancer, 2009, 16, 267-279.	3.1	33

#	Article	IF	Citations
37	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy, 2019, 11, 167-175.	2.0	33
38	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 397-408.	2.3	32
39	Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World Journal of Hepatology, 2018, 10, 433-447.	2.0	31
40	PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nature Communications, 2019, 10, 2484.	12.8	30
41	Coriolus versicolor (Yunzhi) Use as Therapy in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function or Who Are Unfit for Standard Therapy. Journal of Alternative and Complementary Medicine, 2017, 23, 648-652.	2.1	29
42	Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 9-21.	7.7	29
43	Gastric peritoneal carcinomatosis - a retrospective review. World Journal of Gastrointestinal Oncology, 2017, 9, 121.	2.0	27
44	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	3.7	27
45	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut, 2022, 71, 1277-1288.	12.1	23
46	Electroacupuncture for Refractory Acute Emesis Caused by Chemotherapy. Journal of Alternative and Complementary Medicine, 2006, 12, 963-969.	2.1	21
47	Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer, 2016, 16, 856.	2.6	20
48	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept â€œ3Gâ€•Trial. Clinical Cancer Research, 2018, 24, 5272-5281.	7.0	20
49	201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. International Journal of Hyperthermia, 2017, 33, 288-294.	2.5	19
50	Realâ€world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e249-e261.	1.1	18
51	Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities. Molecular and Clinical Oncology, 2013, 1, 190-194.	1.0	17
52	Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook. Journal of Global Oncology, 2018, 4, 1-8.	0.5	17
53	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	17
54	Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World Journal of Gastroenterology, 2010, 16, 3709.	3.3	16

#	Article	IF	Citations
55	Breast Lymphoma: Favorable Prognosis after Treatment with Standard Combination Chemotherapy. Oncology Research and Treatment, 2006, 29, 14-18.	1.2	15
56	Gastrointestinal stromal tumour in the elderly. Critical Reviews in Oncology/Hematology, 2009, 70, 256-261.	4.4	14
57	Metastatic gastric cancer: Does the site of metastasis make a difference?. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 10-17.	1.1	14
58	Activity of Thalidomide and Capecitabine in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 222-227.	1.3	13
59	Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series. , 2019, 7, 162.		13
60	Capecitabine-induced oromandibular dystonia: A case report and literature review. Acta OncolÃ³gica, 2008, 47, 1161-1165.	1.8	11
61	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. Liver Cancer, 2022, 11, 426-439.	7.7	11
62	Comparison of health state values derived from patients and individuals from the general population. Quality of Life Research, 2017, 26, 3353-3363.	3.1	10
63	Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases (Basel, Switzerland), 2015, 3, 306-324.	2.5	9
64	Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 141-150.	2.3	8
65	Potentially Functional SNPs (pfSNPs) as Novel Genomic Predictors of 5-FU Response in Metastatic Colorectal Cancer Patients. PLoS ONE, 2014, 9, e111694.	2.5	8
66	Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 275-283.	1.1	8
67	Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery, 2018, 163, 1008-1013.	1.9	8
68	A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2012, 70, 583-590.	2.3	6
69	Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. ESMO Open, 2021, 6, 100129.	4.5	6
70	The fibroblast growth factor receptor pathway in hepatocellular carcinoma. Hepatoma Research, 2018, 4, 52.	1.5	6
71	Hypoglycaemia in a 63-Year-Old Female with a Large, Recurrent, Metastatic Gastrointestinal Stromal Tumour (GIST). Journal of Gastrointestinal Cancer, 2011, 42, 263-265.	1.3	4
72	Do elderly patients benefit from enrollment into Phase I Trials?. Journal of Geriatric Oncology, 2015, 6, 241-248.	1.0	4

#	Article	IF	Citations
73	Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 224-239.	7.7	4
74	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Studyâ€"An Asian Tertiary Cancer Center Experience. JCO Precision Oncology, 2021, 5, 859-875.	3.0	4
75	Microarray-based tumor molecular profiling to direct choice of cisplatin plus S-1 or oxaliplatin plus S-1 for advanced gastric cancer: A multicentre, prospective, proof-of-concept phase 2 trial.. Journal of Clinical Oncology, 2017, 35, 48-48.	1.6	4
76	Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. Journal of Thoracic Oncology, 2009, 4, 988-993.	1.1	3
77	Rapamycin and Thalidomide Treatment of a Patient with Refractory Metastatic Gastroesophageal Adenocarcinoma: A Case Report. Oncologist, 2010, 15, 965-968.	3.7	3
78	Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. Liver Cancer, 2022, 11, 451-459.	7.7	3
79	Increased Î±-Fetoprotein Likely Induced by Complementary Health Products. Journal of Clinical Oncology, 2013, 31, e80-e82.	1.6	2
80	Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. Annals of Oncology, 2017, 28, iii139.	1.2	2
81	Resected pancreatic adenocarcinoma: An Asian institution's experience. Cancer Reports, 2021, 4, e1393.	1.4	2
82	Letters to the editor: The not so innocuous abdominal tap. Palliative Medicine, 2007, 21, 62-62.	3.1	1
83	Deconvolution assessment of splenic and splanchnic contributions to portal venous blood flow in liver cirrhosis. Medical Physics, 2011, 38, 2768-2782.	3.0	1
84	Mucosal and Subcutaneous Metastasis from Hepatocellular Carcinoma: A Case Report. Proceedings of Singapore Healthcare, 2014, 23, 306-308.	0.6	1
85	Novel Targets in Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 192-198.	0.5	1
86	What is the value of thirdâ€line chemotherapy in advanced gastroesophageal cancer? A 5â€year retrospective analysis at a single center. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 23-27.	1.1	1
87	Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. Gastrointestinal Cancer Research: GCR, 2008, 2, 96-7.	0.7	1
88	Atezolizumab and bevacizumab for <scp>HCC</scp> in the real world. Liver International, 2022, 42, 727-728.	3.9	1
89	An Alternative Therapy for Patients with Hepatic Impairment?. Oncology Research and Treatment, 2007, 30, 474-475.	1.2	0
90	Hepatic artery infusion in the treatment of colorectal cancer metastases. Current Colorectal Cancer Reports, 2008, 4, 106-113.	0.5	0

#	Article	IF	Citations
91	SIRT-Y90 followed by gemcitabine plus cisplatin for Intra-hepatic cholangiocarcinoma: a phase II study. Annals of Oncology, 2015, 26, vii121.	1.2	0
92	Challenges of Cancer Care in Singapore. Annals of Oncology, 2019, 30, vi5.	1.2	0
93	A phase 1b study of <scp>OXIRI</scp> in pancreatic adenocarcinoma patients and its immunomodulatory effects. International Journal of Cancer, 2022, , .	5.1	0